SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility

Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda

SCHOTT Pharma AG & Co. KGaA: Dr. Jens Schulte, sell

SCHOTT Pharma reports good start into fiscal year 2024

SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance

Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company

SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Option

SCHOTT Pharma AG & Co. KGaA: Andreas Reisse, buy

SCHOTT Pharma AG & Co. KGaA: Ann-Kristin Erkens, buy

SCHOTT Pharma AG & Co. KGaA: Dr. Almuth Steinkühler, buy

SCHOTT Pharma AG & Co. KGaA: Dr. Jens Schulte, buy

SCHOTT Pharma AG & Co. KGaA: Dr. Wolfgang Wienand, buy

SCHOTT Pharma AG & Co. KGaA: Peter Goldschmidt, buy

Release of the Home Member State according to Article 5 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

SCHOTT Pharma IPO: Final offer price set at EUR 27.00 per share

SCHOTT Pharma AG & Co. KGaA: Final offer price for shares in SCHOTT Pharma set at EUR 27.00 per share

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma shares to be offered within price range of EUR 24.50 to EUR 28.50 per share

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma plans Initial Public Offering

SCHOTT Pharma AG & Co. KGaA: Upholding momentum: SCHOTT Pharma sustains strong growth in the first half of FY 2023

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma with strong financial performance in fiscal year 2022